BioXcel Therapeutics (BTAI) Share-based Compensation (2017 - 2026)

BioXcel Therapeutics has reported Share-based Compensation for 10 years, with the latest figure at $467000.0 in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 69.99% year-over-year to $467000.0 in Q2 2026; TTM through Jun 2026 was $467000.0, a 95.79% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 64.02% from the prior year.
• Share-based Compensation was $467000.0 for Q2 2026 at BioXcel Therapeutics, down from $512000.0 in the prior quarter.
• The five-year high for Share-based Compensation was $6.1 million in Q2 2023, with the low at -$199000.0 in Q4 2024.
• Average Share-based Compensation over 5 years is $3.2 million, with a median of $4.5 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation plunged 105.53% in 2024, then surged 326.13% in 2025.
• Over 5 years, Share-based Compensation stood at $4.5 million in 2022, then declined by 20.85% to $3.6 million in 2023, then tumbled by 105.53% to -$199000.0 in 2024, then soared by 326.13% to $450000.0 in 2025, then gained by 3.78% to $467000.0 in 2026.
• The last three Share-based Compensation figures came in at $467000.0 (Q2 2026), $512000.0 (Q1 2026), and $450000.0 (Q4 2025), per Business Quant data.